



Attorney Docket No.: 4759.224-US

PATENT

TECH CENTER 1600/2900

NOV 08 2002

RECEIVED

7  
V03  
11-20-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Serial No.: 09/940,963

Group Art Unit: 1626

Filed: August 28, 2001

Examiner: Robert Gerstl

For: Heterocyclic Compounds and their Preparation and Use

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

It is respectfully requested that the time for response to the Office Action dated May 3, 2002, having a shortened statutory period for reply set to expire August 3, 2002, be extended for a period of three (3) months to November 3, 2002, to permit timely filing of the Amendment/Response enclosed herewith.

Please charge the required fee estimated to be \$920.00, and any additional fees which may be required for this petition, and credit any overpayments to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: October 31, 2002

11/07/2002 MBIZUNES 00000118 141447 09940963  
01 FC:1253 920.00 CH

Rosemarie R. Wilk-Orescan  
Registration Number 45,220  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5969